Betaine anhydrous in homocystinuria: results from the RoCH registry
Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn erro...
Gespeichert in:
| Veröffentlicht in: | Orphanet journal of rare diseases Jg. 14; H. 1; S. 66 - 10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
14.03.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1750-1172, 1750-1172 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.
Results
A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns.
Conclusions
Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. |
|---|---|
| AbstractList | The Registry of Adult and Paediatric Patients Treated with Cystadane[R] - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane[R]) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [[less than or equai to]18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 [+ or -] 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine [beta]-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. BACKGROUND: The Registry of Adult and Paediatric Patients Treated with Cystadane(R) - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane(R)) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.RESULTS: A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [</=18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 +/- 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine beta-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns.CONCLUSIONS: Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. The Registry of Adult and Paediatric Patients Treated with Cystadane® - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. Results A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Conclusions Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. Background The Registry of Adult and Paediatric Patients Treated with Cystadane[R] - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane[R]) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. Results A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [[less than or equai to]18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 [+ or -] 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine [beta]-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Conclusions Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. Keywords: Betaine anhydrous, Efficacy, Homocystinuria, RoCH registry, Safety Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. Results A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Conclusions Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. Abstract Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year. Results A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns. Conclusions Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. The Registry of Adult and Paediatric Patients Treated with Cystadane® - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.BACKGROUNDThe Registry of Adult and Paediatric Patients Treated with Cystadane® - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane®) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns.RESULTSA total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [≤18 years]: 75) were enrolled at 29 centres in France and Spain. Patients were treated with betaine anhydrous for a mean duration of 7.4 ± 4.3 years. The median total daily dose of betaine anhydrous at the first and last study visits was 6 g/day for cystathionine β-synthase (CBS)-deficient vitamin B6 responders and 9 g/day for methylenetetrahydrofolate reductase-deficient patients, while the median daily dose increased in CBS-deficient B6 non-responders (from 6 to 9 g/day) and cobalamin metabolism-defective patients (from 3 to 6 g/day) between the first and last visits. Treatment caused a mean overall reduction of 29% in plasma homocysteine levels in the study population. A total of 277 AEs were reported during the study, of which two non-serious AEs (bad taste and headache) and one serious AE (interstitial lung disease) were considered to be drug related. Overall, betaine anhydrous was well tolerated with no major safety concerns.Data from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients.CONCLUSIONSData from the RoCH registry provided real-world evidence on the clinical safety and efficacy of betaine anhydrous in the management of homocystinuria in paediatric and adult patients. |
| ArticleNumber | 66 |
| Audience | Academic |
| Author | Eyer, Didier Damaj, Léna Maillot, François Dalmau, Jaime García-Cazorla, Angels Couce, Maria L. Hiéronimus, Sylvie Levrat, Virginie Rigalleau, Vincent Touati, Guy Nadjar, Yann Cano, Aline Aldamiz-Echevarria, Luis Cathebras, Pascal Peña-Quintana, Luis Dobbelaere, Dries Guffon, Nathalie Brunet, Dominique Martinez-Pardo Casanova, Mercedes Valayannopoulos, Vassili Schiff, Manuel Gay, Claire |
| Author_xml | – sequence: 1 givenname: Vassili orcidid: 0000-0003-3942-8234 surname: Valayannopoulos fullname: Valayannopoulos, Vassili email: vassilival.boston@gmail.com organization: Hôpital Necker-Enfants Malades, Sanofi Genzyme – sequence: 2 givenname: Manuel surname: Schiff fullname: Schiff, Manuel organization: Hôpital Robert Debré – sequence: 3 givenname: Nathalie surname: Guffon fullname: Guffon, Nathalie organization: Hôpital Femme Mère Enfant – sequence: 4 givenname: Yann surname: Nadjar fullname: Nadjar, Yann organization: Hôpital Pitié-Salpêtrière – sequence: 5 givenname: Angels surname: García-Cazorla fullname: García-Cazorla, Angels organization: Hospital St Joan de Déu – sequence: 6 givenname: Mercedes surname: Martinez-Pardo Casanova fullname: Martinez-Pardo Casanova, Mercedes organization: Hospital Universitario Ramon y Cajal – sequence: 7 givenname: Aline surname: Cano fullname: Cano, Aline organization: Center of Reference for Inborn Metabolic Disease, CHU La Timone – sequence: 8 givenname: Maria L. surname: Couce fullname: Couce, Maria L. organization: Hospital Clínico Universitario – sequence: 9 givenname: Jaime surname: Dalmau fullname: Dalmau, Jaime organization: Hospital Universitario y Politécnico La Fe – sequence: 10 givenname: Luis surname: Peña-Quintana fullname: Peña-Quintana, Luis organization: Hospital Universitario Materno-Infantil, Universidad de Las Palmas de Gran Canaria, CIBER OBN – sequence: 11 givenname: Vincent surname: Rigalleau fullname: Rigalleau, Vincent organization: Hôpital Haut Leveque – sequence: 12 givenname: Guy surname: Touati fullname: Touati, Guy organization: Hôpital des Enfants – sequence: 13 givenname: Luis surname: Aldamiz-Echevarria fullname: Aldamiz-Echevarria, Luis organization: Hospital Universitario Cruces-Osakidetza – sequence: 14 givenname: Pascal surname: Cathebras fullname: Cathebras, Pascal organization: CHU Hôpital Nord – sequence: 15 givenname: Didier surname: Eyer fullname: Eyer, Didier organization: CHU Hautepierre – sequence: 16 givenname: Dominique surname: Brunet fullname: Brunet, Dominique organization: CHU La Timone – sequence: 17 givenname: Léna surname: Damaj fullname: Damaj, Léna organization: CHU Hôpital Sud – sequence: 18 givenname: Dries surname: Dobbelaere fullname: Dobbelaere, Dries organization: Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital and RADEME Research Team for Rare Metabolic and Developmental Diseases – sequence: 19 givenname: Claire surname: Gay fullname: Gay, Claire organization: CHU Hôpital Nord – sequence: 20 givenname: Sylvie surname: Hiéronimus fullname: Hiéronimus, Sylvie organization: Hôpital l’Archet – sequence: 21 givenname: Virginie surname: Levrat fullname: Levrat, Virginie organization: Centre Hospitalier Annecy Genevois – sequence: 22 givenname: François surname: Maillot fullname: Maillot, François organization: CHRU de Tours, Service de Médecine Interne, Université François Rabelais |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30871635$$D View this record in MEDLINE/PubMed https://hal.science/hal-03169091$$DView record in HAL |
| BookMark | eNp9kl1v0zAYhSM0xLbCD-AGReKGXWT4I4ltLpBKBbRSJaQB15btOKmr1B62M9F_j7OM0VaAIiXR6-ccOyfnMjuzzuosewnBNYS0fhsgBggXALICAlwX6El2AUkFCggJOjt4P88uQ9gCUFYY0GfZeboTWOPqIlt80FEYq3NhN_vGuyHkxuYbt3NqH6KxgzfiXe51GPoY8ta7XR43Or9xi2WadiZEv3-ePW1FH_SLh-cs-_7p47fFslh_-bxazNeFIpjEAsuqAXVLpCxrKFUpEKAlZbJBFaVpUamKSSlbQJEqWaUgAFi1hEmkqzRBeJatJt_GiS2_9WYn_J47Yfj9wPmOCx-N6jUHVVMyVUtVM1ZKCgURSmJaC8Q0KiVJXu8nr9tB7nSjtI1e9EemxyvWbHjn7nhdQlamHGfZ1WSwOZEt52s-zgCGNQMM3sHEvnnYzLsfgw6R70xQuu-F1SlxjiAbYcrGc70-Qbdu8DbFek8RXBNyQHUifayxrUtnVKMpn1cUpuMhOuZ1_RcqXY3eGZWq1Jo0PxJcHQkSE_XP2IkhBL76enPMvjoM8DGC39VKAJwA5V0IXrePCAR8rC-f6stTfflYXz6akhONMlFE48Z_YPr_KtGkDGkX22n_J7d_i34BDNz_Ag |
| CitedBy_id | crossref_primary_10_3390_nu15092112 crossref_primary_10_1002_jmd2_12092 crossref_primary_10_3389_fddev_2025_1553286 crossref_primary_10_3390_biom10081119 crossref_primary_10_1007_s40278_019_60000_3 crossref_primary_10_1016_j_cca_2020_06_014 crossref_primary_10_3390_nu12092895 crossref_primary_10_3390_nu15143105 crossref_primary_10_1007_s00394_021_02738_2 crossref_primary_10_2106_JBJS_RVW_20_00245 crossref_primary_10_1007_s11064_022_03622_z crossref_primary_10_1186_s13023_022_02567_4 crossref_primary_10_3390_nu16010135 crossref_primary_10_1097_MCO_0000000000000705 |
| Cites_doi | 10.1007/s10545-006-0106-5 10.1056/NEJM198308253090802 10.1016/0026-0495(85)90156-8 10.1007/s10545-016-9979-0 10.1007/s10545-016-9991-4 10.1002/humu.9153 10.2147/ODRR.S27597 10.1016/j.jpeds.2003.12.041 10.1007/PL00014310 10.1001/jamaneurol.2013.4915 10.1007/s10545-011-9364-y 10.1007/PL00014307 10.1620/tjem.237.323 10.1016/S0022-3476(81)80352-6 10.1055/s-0032-1329883 10.1007/s10545-010-9161-z 10.1007/s10545-014-9687-6 10.1007/PL00014308 10.1111/j.1365-2141.2009.07937.x 10.1542/peds.2006-1783 10.1023/A:1005353530303 10.1007/s10545-010-9177-4 10.7314/APJCP.2012.13.11.5333 10.1002/ajmg.10186 10.1002/ajmg.c.30288 10.1136/bmj.313.7064.1025 10.1161/01.ATV.20.5.1199 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. licence_http://creativecommons.org/publicdomain/zero |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: licence_http://creativecommons.org/publicdomain/zero |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s13023-019-1036-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1750-1172 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_05d49c6bc6994b81a7acb386a29e24b7 PMC6419445 oai:HAL:hal-03169091v1 A581453282 30871635 10_1186_s13023_019_1036_2 |
| Genre | Multicenter Study Research Support, Non-U.S. Gov't Journal Article Observational Study |
| GeographicLocations | France Spain Europe |
| GeographicLocations_xml | – name: Spain – name: France – name: Europe |
| GrantInformation_xml | – fundername: Orphan Europe-Ricordati – fundername: ; |
| GroupedDBID | --- 0R~ 123 29N 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BNQBC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 1XC 2VQ 4.4 AHSBF H13 IPNFZ RIG VOOES 5PM |
| ID | FETCH-LOGICAL-c737t-3b5d06f7bb461bc4a208489bd25883b5cc59bbbf082c495c1003cf79b2e52c423 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000461282500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1750-1172 |
| IngestDate | Fri Oct 03 12:39:55 EDT 2025 Tue Nov 04 01:45:29 EST 2025 Mon Nov 24 06:20:26 EST 2025 Wed Oct 01 14:06:30 EDT 2025 Mon Oct 20 01:43:49 EDT 2025 Tue Nov 11 10:41:04 EST 2025 Tue Nov 04 17:48:38 EST 2025 Thu Nov 13 15:10:51 EST 2025 Thu Jan 02 22:58:43 EST 2025 Sat Nov 29 03:40:38 EST 2025 Tue Nov 18 21:33:45 EST 2025 Sat Sep 06 07:29:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Betaine anhydrous RoCH registry Efficacy Homocystinuria Safety |
| Language | English |
| License | licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c737t-3b5d06f7bb461bc4a208489bd25883b5cc59bbbf082c495c1003cf79b2e52c423 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-3942-8234 0000-0001-7570-3366 0000-0002-5175-6479 |
| OpenAccessLink | https://link.springer.com/10.1186/s13023-019-1036-2 |
| PMID | 30871635 |
| PQID | 2193736777 |
| PQPubID | 76088 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_05d49c6bc6994b81a7acb386a29e24b7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6419445 hal_primary_oai_HAL_hal_03169091v1 proquest_miscellaneous_2193169897 proquest_journals_2193736777 gale_infotracmisc_A581453282 gale_infotracacademiconefile_A581453282 gale_incontextgauss_ISR_A581453282 pubmed_primary_30871635 crossref_primary_10_1186_s13023_019_1036_2 crossref_citationtrail_10_1186_s13023_019_1036_2 springer_journals_10_1186_s13023_019_1036_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-03-14 |
| PublicationDateYYYYMMDD | 2019-03-14 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Orphanet journal of rare diseases |
| PublicationTitleAbbrev | Orphanet J Rare Dis |
| PublicationTitleAlternate | Orphanet J Rare Dis |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | 1036_CR14 AM Devlin (1036_CR26) 2004; 144 DE Wilcken (1036_CR7) 1985; 34 DE Wilcken (1036_CR8) 1983; 309 AA Morris (1036_CR1) 2017; 40 DE Wilcken (1036_CR23) 2000; 20 EV Quadros (1036_CR13) 2010; 148 D Martinelli (1036_CR15) 2011; 34 JH Walter (1036_CR6) 1998; 157 SH Mudd (1036_CR10) 1985; 37 CI Kaye (1036_CR30) 2006; 118 R Yaghmai (1036_CR27) 2002; 108 R Castro (1036_CR5) 2006; 29 LA Smolin (1036_CR20) 1981; 99 S Fischer (1036_CR18) 2014; 37 DM Isherwood (1036_CR22) 1996; 313 R Urreizti (1036_CR9) 2003; 22 1036_CR17 1036_CR16 SJ Sacharow (1036_CR28) 1993 H Ogier de Baulny (1036_CR32) 1998; 157 DS Rosenblatt (1036_CR33) 1997; 20 1036_CR21 EF Diekman (1036_CR19) 2014; 71 XY Wu (1036_CR11) 2012; 13 A Devlin (1036_CR24) 2004; 144 E Naughten (1036_CR29) 1998; 157 HJ Blom (1036_CR12) 2011; 34 KN Maclean (1036_CR3) 2012; 2012 H Sasai (1036_CR25) 2015; 237 N Carrillo-Carrasco (1036_CR31) 2012; 35 M Huemer (1036_CR2) 2017; 40 M Schiff (1036_CR4) 2012; 43 |
| References_xml | – volume: 29 start-page: 3 year: 2006 ident: 1036_CR5 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-006-0106-5 – ident: 1036_CR17 – ident: 1036_CR21 – volume: 309 start-page: 448 year: 1983 ident: 1036_CR8 publication-title: N Engl J Med doi: 10.1056/NEJM198308253090802 – volume: 34 start-page: 1115 year: 1985 ident: 1036_CR7 publication-title: Metabolism. doi: 10.1016/0026-0495(85)90156-8 – volume: 40 start-page: 49 year: 2017 ident: 1036_CR1 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-016-9979-0 – volume: 40 start-page: 21 year: 2017 ident: 1036_CR2 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-016-9991-4 – volume: 22 start-page: 103 year: 2003 ident: 1036_CR9 publication-title: Hum Mutat doi: 10.1002/humu.9153 – volume: 2012 start-page: 23 year: 2012 ident: 1036_CR3 publication-title: Orphan Drugs Res Rev doi: 10.2147/ODRR.S27597 – volume-title: GeneReviews® year: 1993 ident: 1036_CR28 – volume: 144 start-page: 545 year: 2004 ident: 1036_CR26 publication-title: J Pediatr doi: 10.1016/j.jpeds.2003.12.041 – volume: 144 start-page: 545 year: 2004 ident: 1036_CR24 publication-title: J Pediatr doi: 10.1016/j.jpeds.2003.12.041 – volume: 157 start-page: S84 year: 1998 ident: 1036_CR29 publication-title: Eur J Pediatr doi: 10.1007/PL00014310 – volume: 71 start-page: 188 year: 2014 ident: 1036_CR19 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2013.4915 – volume: 35 start-page: 91 year: 2012 ident: 1036_CR31 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-011-9364-y – volume: 157 start-page: S77 issue: Suppl 2 year: 1998 ident: 1036_CR32 publication-title: Eur J Pediatr doi: 10.1007/PL00014307 – volume: 237 start-page: 323 year: 2015 ident: 1036_CR25 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.237.323 – volume: 99 start-page: 467 year: 1981 ident: 1036_CR20 publication-title: J Pediatr doi: 10.1016/S0022-3476(81)80352-6 – volume: 43 start-page: 295 year: 2012 ident: 1036_CR4 publication-title: Neuropediatrics. doi: 10.1055/s-0032-1329883 – ident: 1036_CR16 – volume: 34 start-page: 127 year: 2011 ident: 1036_CR15 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-010-9161-z – volume: 37 start-page: 831 year: 2014 ident: 1036_CR18 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-014-9687-6 – volume: 157 start-page: S71 issue: Suppl 2 year: 1998 ident: 1036_CR6 publication-title: Eur J Pediatr doi: 10.1007/PL00014308 – volume: 148 start-page: 195 year: 2010 ident: 1036_CR13 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2009.07937.x – volume: 118 start-page: e934 year: 2006 ident: 1036_CR30 publication-title: Pediatrics. doi: 10.1542/peds.2006-1783 – volume: 20 start-page: 528 year: 1997 ident: 1036_CR33 publication-title: J Inherit Metab Dis doi: 10.1023/A:1005353530303 – volume: 34 start-page: 75 year: 2011 ident: 1036_CR12 publication-title: J Inherit Metab Dis doi: 10.1007/s10545-010-9177-4 – volume: 13 start-page: 5333 year: 2012 ident: 1036_CR11 publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2012.13.11.5333 – volume: 37 start-page: 1 year: 1985 ident: 1036_CR10 publication-title: Am J Hum Genet – volume: 108 start-page: 57 year: 2002 ident: 1036_CR27 publication-title: Am J Med Genet doi: 10.1002/ajmg.10186 – ident: 1036_CR14 doi: 10.1002/ajmg.c.30288 – volume: 313 start-page: 1025 year: 1996 ident: 1036_CR22 publication-title: BMJ. doi: 10.1136/bmj.313.7064.1025 – volume: 20 start-page: 1199 year: 2000 ident: 1036_CR23 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.20.5.1199 |
| SSID | ssj0045308 |
| Score | 2.3454556 |
| Snippet | Background
The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre,... The Registry of Adult and Paediatric Patients Treated with Cystadane® - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre,... The Registry of Adult and Paediatric Patients Treated with Cystadane[R] - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre,... Background The Registry of Adult and Paediatric Patients Treated with Cystadane[R] - Homocystinuria (RoCH) is a non-interventional, observational,... Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational, multi-centre,... BACKGROUND: The Registry of Adult and Paediatric Patients Treated with Cystadane(R) - Homocystinuria (RoCH) is a non-interventional, observational,... Abstract Background The Registry of Adult and Paediatric Patients Treated with Cystadane® – Homocystinuria (RoCH) is a non-interventional, observational,... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 66 |
| SubjectTerms | Adolescent Adult Amino acids Betaine Betaine - administration & dosage Betaine - adverse effects Betaine anhydrous Care and treatment Child Child, Preschool Defects Edema Efficacy Endocrinology and metabolism Female France Headache Health aspects Homocysteine Homocysteine - blood Homocystinuria Homocystinuria - drug therapy Human Genetics Human health and pathology Humans Inborn errors of metabolism Infant Inherited metabolic diseases Life Sciences Lung diseases Male Medical prognosis Medical research Medical screening Medicine Medicine & Public Health Metabolism Metabolites Methylenetetrahydrofolate reductase NMR Non-pharmacological intervention Nuclear magnetic resonance Patient monitoring equipment Patients Pediatrics Pharmaceutical sciences Pharmacology Pharmacology/Toxicology Plasma Population studies Rare diseases Registries Respiratory tract diseases Retrospective Studies Risk factors RoCH registry Safety Santé publique et épidémiologie Spain Studies Treatment Outcome Vitamin B12 Vitamin B6 Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9aRHwRv722SiyCoCzdZLP58O16WE7QIlWhbyHJZXsHNSu3d4X-987s7p2uRX3xNZnsJjO_SWbIZIaQlyYEHjkooARbIhNVlJmHkyHT4Ao4GMKVCW2xCXVyos_OzKdfSn1hTFiXHrhj3GFezoQJ0gdpjPCaOeWCL7R03EQufPuOHKyejTPV7cGiLHLd32EyLQ8bvJ7DuCED204hMz44hdpk_dst-eYcIyKvm5vXoyZ_uzptT6Tje-Rub0rScbeE--RGTA_I7Y_9ZflDMjnC8NAUqUvzq9kSXHy6SHRef6vDFSh2WgP23lJwt9cXq4biOxMK1iA9rSdTivUasAzcI_L1-N2XyTTrayZkQRVqlRW-nOWyUt4LyXwQjmPCfONnvNQaOkMojfe-gpM_gG8UGGh1qJTxPJbQwovHZCfVKT4lVOSuklUUBQgQjCrhKhM1Y7LKWVTGlSOSb3hoQ59QHOtaXNjWsdDSdmy3wHaLbLd8RF5vh3zvsmn8jfgIBbMlxETYbQPAw_bwsP-Cx4gcoFgtprpIGEtz7tZNY99_PrXjUjMACvicI_KqJ6pqWEFw_dME4ANmxxpQ7g8oQRfDoPsA0DOY8XT8wWIbbJ7SgHF2yeAbG3DZfsNoLBwchSqkUjDjF9tu_DwGwaUIGGlpGBb8BJonHRa3v8LEjmBag1DUAKWDuQx70mLephOXghkhYOSbDZ5_TuuPwtn9H8LZI3c46iSGR4p9srNaruMzcitcrhbN8nmr0T8AgOlKdw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYhxAvfA8KA4UJCQkULXEcf_CC2mpTkaCaCkh7s2zHWSuNZDTtpP333KVupzCxF17tc2r3fne-y13uCHmnnKOeggBysCViVnoeW7gZYgmugIElVCjXNpsQk4k8PVUn4YVbE9IqNzqxVdRF7fAd-SFIViYyLoT4fPE7xq5RGF0NLTR2yC5WKmM9sjs8mpxMN7qY5VkiQywzlfywwTAd5g8pUD8Zj2nnNmqL9m9V884MMyNvmp03syf_CqG2N9Pxw_890yPyINik0WANosfkjq-ekHvfQtT9KRkNMc-08pGpZlfFol410byKZvWv2l2BhqhWAOJPEfjtq_NlE-EHKxGYldG0Ho0jbPyA_eSekZ_HRz9G4zg0X4idyMQyzmxeJLwU1jKeWscMxcr7yhY0lxImncuVtbYEE8KBk-VSUA-uFMpSn8MIzfZIr6or_4JELDElLz3LAAlgnTFTKi_TlJdJ6oUyeZ8kGyZoFyqTY4OMc916KJLrNd808E0j3zTtkw_bJRfrshy3EQ-Rs1tCrKjdDtSLMx0EVCd5wZTj1nGlmJWpEcbZTHJDlafMij45QFxorJlRYVLOmVk1jf7yfaoHuUwBaeC89sn7QFTWcAJnwjcO8D9gma0O5X6HEoTadaYPAH6dHY8HXzWOgRbmCqy8yxSesYGVDpqn0deY6pO322l8PGbTVR4w0tKk2DkUaJ6vwbz9KawQCTY6MEV0YN7ZS3emms_auuScgQgyWPlxIxDX2_onc17efohX5D5FccUMSrZPesvFyr8md93lct4s3gRx_wOiclnV priority: 102 providerName: ProQuest |
| Title | Betaine anhydrous in homocystinuria: results from the RoCH registry |
| URI | https://link.springer.com/article/10.1186/s13023-019-1036-2 https://www.ncbi.nlm.nih.gov/pubmed/30871635 https://www.proquest.com/docview/2193736777 https://www.proquest.com/docview/2193169897 https://hal.science/hal-03169091 https://pubmed.ncbi.nlm.nih.gov/PMC6419445 https://doaj.org/article/05d49c6bc6994b81a7acb386a29e24b7 |
| Volume | 14 |
| WOSCitedRecordID | wos000461282500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Contemporary customDbUrl: eissn: 1750-1172 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0045308 issn: 1750-1172 databaseCode: RSV dateStart: 20061201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1raxNBcLGtiF98a6M1nEUQlKP32NuH35LQkoINIVWJn5bdzV4TqHcllxT6753Z3EXOqqBfAtmdvezNzjMzO0PIW2lt4hJgQAa2REhzx0IDmiEU4ApoWJJwaX2zCT4aielUjut73FWT7d6EJL2k9mwt2FGFITbM_ZEgOlIWgtzdA20nkBsn518b8UuzNBJ1-PK3y1oKyNfp30rjnTkmQ962NG8nTP4SNfXK6OThf73GI_Kgtj2D3oZYHpM7rnhC7p3V0fWnZNDHfNLCBbqY38yW5boKFkUwL7-X9gYkQbEGYv0YgH--vlxVAV5MCcB8DCblYBhggwfsG_eMfDk5_jwYhnWThdDylK_C1GSziOXcGMpiY6lOsMK-NLMkEwImrc2kMSYHU8GCM2VjEAM259IkLoORJH1OdouycPskoJHOWe5oCicOVhjVuXQijlkexY5LnXVI1GBe2boCOTbCuFTeExFMbZCjADkKkaOSDnm_XXK1Kb_xN-A-HucWECtn-4FyeaFqRlRRNqPSMmOZlNSIWHNtTSqYTqRLqOEdcojEoLA2RoHJNxd6XVXq9HyiepmIgbzASe2QdzVQXsIbWF3fZQA8YDmtFuRBCxKY17amD4HmWjse9j4pHANpyyRYc9cxPKMhSVVLmEqBpkl5yjiHHb_ZTuPjMWuucEAjHibGDqEA82JDwdufwkqQYIvDofAWbbf20p4pFnNff5zRWFIKKz80FP5zW388nJf_BP2K3E-QRTBxkh6Q3dVy7V6Tu_Z6taiWXbLDp9x_ii7Z6x-PxpOu_zMFvo1Pz8bful4k_AD_3lPR |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGh4AX7pfCgDCBkEDRGsfxBQmhrjC1WltN25DGk4ldZ600ktG0Q_1T_EbOSZNOYWJve-DVPk7s-Du3-PgcQl4ra6mjwIAcbAmfJY77BjSDL8EViGEIFcoWxSbEcCiPjtTeGvld3YXBsMpKJhaCepRZ_Ee-BZwVipALIT6d_vSxahSerlYlNJaw2HWLX-Cy5R97n2F_31C68-Ww0_XLqgK-FaGY-aGJRi2eCGMYD4xlMcWU8sqMaCQldFobKWNMArrRgvdgA8C9TYQy1EXQgokOQOSvMwC7bJD1vd5g71sl-1kUtmR5dhpIvpXjsSDGKykQdyH3aU37FUUCVqrg2hgjMS-auRejNf86si004c6d_-0b3iW3S5vbay-Z5B5Zc-l9cmNQRhU8IJ1tjKNNnRen48Voms1zb5J64-xHZhcgAdM5MOkHb-ry-cks9_BCjgdms7efdboeFrbAenkPydcrWcIj0kiz1D0hHmvFCU8cCwHpYH2yOFFOBgFPWoETKo6apFVturZl5nUsAHKiCw9Mcr3EiQacaMSJpk3ybjXkdJl25DLibUTSihAzhhcN2fRYlwJIt6IRU5Yby5ViRgaxiK0JJY-pcpQZ0SSbiEONOUFSDDo6jud5rnsH-7odyQCQDc55k7wtiZIMVmDj8g4HfAdMI1aj3KhRgtCyte5NgHttxt12X2MbaBmuwIo9C-AZFYx1KVlzfY7hJnm16sbHY7Rg6gAjBU2AlVGB5vGSeVavwgyY4IPApogaW9XmUu9JJ-Mi7zpngWIMRr6vGPB8Wv_cnKeXL-Iludk9HPR1vzfcfUZuURQVGC3KNkhjNp275-S6PZtN8umLUtR45PtVc-Yfahi2jA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3raxQxEA9apfjF9-O06loEQVm6m83m4bfrabliPUqr0m8hyWV7BzVbbu8K_e-d2cfJWhXEr8lkN4_fTGaYyQwhr5Vz1FNgQA66RMwKz2MLN0MswRQwMIQK5epiE2IykScn6rCtc1p10e6dS7J504BZmsJy53xaNCwu-U6F7jaMA1IgRjIegwy-wbBmEJrrx986UczyLJGtK_O3w3qXUZ2zfy2Zr88wMPKq1nk1ePIXD2p9Me3d-e8l3SW3W500GjYgukeu-XCfbH5uve4PyGgX40yDj0yYXU4X5aqK5iGald9LdwkSIqwAxO8jsNtXZ8sqwgcrEaiV0VE5GkdY-AHryT0kX_c-fhmN47b4QuxEJpZxZvNpwgthLeOpdcxQzLyv7JTmUkKnc7my1hagQjgwslwK4sEVQlnqc2ih2SOyEcrgn5CIJabghWcZIAG0M2YK5WWa8iJJvVAmH5CkOwXt2szkWCDjTNcWiuS62RwNm6NxczQdkLfrIedNWo6_Ee_i0a4JMaN23VAuTnXLoDrJp0w5bh1XilmZGmGczSQ3VHnKrBiQbQSGxpwZAYNyTs2qqvT-8ZEe5jIFqIHxOiBvWqKihBU4075xgH3ANFs9yq0eJTC163VvA_56Mx4PDzS2gRTmCrS8ixS-0cFTt5Kn0nADZSLjQsCMX6278fMYTRc8YKSmSbFyKNA8btC8_hVmiAQdHQ5F9HDem0u_J8xndV5yzlLFGIx816H957T-eDhP_4n6Jdk8_LCnD_Ynn56RWxS5BWMr2RbZWC5W_jm56S6W82rxopYDPwArwVmJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Betaine+anhydrous+in+homocystinuria%3A+results+from+the+RoCH+registry&rft.jtitle=Orphanet+journal+of+rare+diseases&rft.au=Valayannopoulos%2C+Vassili&rft.au=Schiff%2C+Manuel&rft.au=Guffon%2C+Nathalie&rft.au=Nadjar%2C+Yann&rft.date=2019-03-14&rft.pub=BioMed+Central+Ltd&rft.issn=1750-1172&rft.eissn=1750-1172&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13023-019-1036-2&rft.externalDocID=A581453282 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1172&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1172&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1172&client=summon |